Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 8

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Feb 28, 2020; 26(8): 818-827
Published online Feb 28, 2020. doi: 10.3748/wjg.v26.i8.818

Table 2 Neoadjuvant therapy and response, n (%)

PR: Partial remission; SD: Stable disease.

Citation: Li Y, Ma FH, Xue LY, Tian YT. Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study. World J Gastroenterol 2020; 26(8): 818-827
URL: https://www.wjgnet.com/1007-9327/full/v26/i8/818.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i8.818

Li Y, Ma FH, Xue LY, Tian YT. Neoadjuvant chemotherapy vs upfront surgery for gastric signet ring cell carcinoma: A retrospective, propensity score-matched study. World J Gastroenterol 2020; 26(8): 818-827 [PMID: 32148379 DOI: 10.3748/wjg.v26.i8.818]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.